Efficacy and Safety Study of Symbicort Turbuhaler in Chinese Patients With COPD

A 6-Month, Phase IIIA, Multi-Center,Randomised,Double-Blind, Double-Dummy, Parallel-Group Study of the Efficacy and Safety of Symbicort® Turbuhaler®+ Bricasol® pMDI Compared With Pulmicort® Turbuhaler®+Bricasol® pMDI in Chinese Patients With COPD

This study aims at evaluating efficacy and safety of Symbicort® Turbuhaler® in Chinese COPD patients as defined by GOLD treatment guidelines in order to obtain an approval for indication of COPD from Chinese State Food and Drug Administration.

Inclusion Criteria:

• Signed and dated inform consent
• Out-patient, clinical diagnosis of COPD
• Men or women at the age of 40 or over

Exclusion Criteria:

• A history of asthma
• Seasonal allergic rhinitis before 40 years of age
• Patients with significant or unstable ischemic heart disease, arrhythmia, cardiomyopathy, heart failure, uncontrolled hypertension as defined by the investigator or other disorder